Sponsor: ADC Therapeutics SA
Sponsor Study ID: ADCT-402-105
Study Title: A Phase 1b Open Label Study to Evaluate the Safety and Anti cancer Activity of Loncastuximab Tesirine in Combination with Other Anti cancer Agents in Patients with Relapsed or Refractory B cell Non Hodgkin Lymphoma (LOTIS 7)
CTO #: 103434
NCT Number: NCT04970901
Phase: I
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Non-Hodgkin's Lymphoma
Study Objectives: The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with gemcitabine, lenalidomide, polazutumab vedotin, or umbralisib, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.